Adalimumab News and Research

RSS
Adalimumab is an injectable prescription drug used to treat diseases of the immune system; it is marketed by Abbot as Humira. It is one of three drugs that work by inhibiting the potent inflammatory molecule tumor necrosis factor-alpha (TNF-alpha); the others are etanercept (Enbrel) and infliximab (Remicade). Like etanercept and infliximab, adalimumab is a large protein molecule made with recombinant DNA technology. Adalimumab is a monoclonal antibody of the IgG1 subtype that has been "humanized", meaning that all of its components are derived from human molecules.
Abbott receives approval for HUMIRA (Adalimumab) for polyarticular juvenile idiopathic arthritis

Abbott receives approval for HUMIRA (Adalimumab) for polyarticular juvenile idiopathic arthritis

Combining medications often best strategy to battle rheumatoid arthritis

Combining medications often best strategy to battle rheumatoid arthritis

Combining medications often best strategy to battle rheumatoid arthritis

Combining medications often best strategy to battle rheumatoid arthritis

New drug shows promise in treating Crohn's disease

New drug shows promise in treating Crohn's disease

Certolizumab pegol effective for patients with Crohn's disease

Certolizumab pegol effective for patients with Crohn's disease

Abbott seeks U.S. and E.U. approvals for Humira as a treatment for juvenile rheumatoid arthritis

Abbott seeks U.S. and E.U. approvals for Humira as a treatment for juvenile rheumatoid arthritis

Adalimumab shows potential for Crohn's disease

Adalimumab shows potential for Crohn's disease

New Crohn's disease treatment Humira promises to reduce symptoms

New Crohn's disease treatment Humira promises to reduce symptoms

FDA approves Humira (adalimumab) for Crohn's disease

FDA approves Humira (adalimumab) for Crohn's disease

Arthritis drugs not as risky as first thought

Arthritis drugs not as risky as first thought

Tumor necrosis factor A antagonist use and cancer in patients with rheumatoid arthritis

Tumor necrosis factor A antagonist use and cancer in patients with rheumatoid arthritis

New rheumatoid arthritis drugs may put patients at risk of infections and cancer

New rheumatoid arthritis drugs may put patients at risk of infections and cancer

Study shows strong association between treatment with TNF-blocking antibodies and development of serious infections

Study shows strong association between treatment with TNF-blocking antibodies and development of serious infections

Evidence supports combination therapy for achieving remission of early rheumatoid arthritis

Evidence supports combination therapy for achieving remission of early rheumatoid arthritis

Adalimumab and methotrexate is about five times more effective than methotrexate alone for rheumatoid arthritis

Adalimumab and methotrexate is about five times more effective than methotrexate alone for rheumatoid arthritis

Abbott receives European approval to market Humira

Abbott receives European approval to market Humira

Biologic treatments to treat the physical symptoms of psoriasis

Biologic treatments to treat the physical symptoms of psoriasis

Tumour Necrosis Factor alpha (TNF-alpha) blocking agents cause skin disease

Tumour Necrosis Factor alpha (TNF-alpha) blocking agents cause skin disease

50,000 people in the U.S. with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery

50,000 people in the U.S. with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery

FDA approves new drug Enbrel for psoriasis

FDA approves new drug Enbrel for psoriasis